CANTON, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: AVR) announced today that at the recent annual meeting held in Dearborn, Michigan, Christine Moore Ph.D. DABCC, Laboratory Director of U.S. Drug Testing Laboratories, an Avitar Company, was elected to the Board of Directors of the Society of Forensic Toxicologists for a three-year term beginning in January 2003.
Dr. Moore is a Fellow of the American Academy of Forensic Sciences, the Royal Society of Chemistry, and the National Association of Clinical Biochemists. She is also board certified in Toxicological Chemistry as a Diplomat of the American Board of Clinical Chemistry. In 2001, Christine held the position of Program Chair for the Toxicology Section of the American Academy of Forensic Sciences, and currently serves as Section Secretary (2002).
"We are pleased that Dr. Moore has been recognized by such a prestigious organization as the Society of Forensic Toxicologists with her election to their Board of Directors," commented Peter P. Phildius, Avitar's Chairman and Chief Executive Officer. "Christine is a key member of Avitar's scientific management team and we enthusiastically support her involvement in organizations such as this."
The Society of Forensic Toxicologists, Inc. (SOFT) is an organization composed of practicing forensic toxicologists and those interested in the discipline, for the purpose of promoting and developing forensic toxicology
The goals of the Society include provision for the establishment and acceptance of uniform qualifications and requirements for the certification and/or licensure of forensic toxicologists by an independent body. Additionally, the Society provides a forum for the discussion and exchange of professional experiences between members and among others engaged in the administration of justice and allied fields, and it actively promotes continuing education and training in forensic toxicology. Dr. Moore is a former Chair of the Continuing Education committee.
About ORALscreen and HAIRscreen
The Company's ORALscreen line represents the most comprehensive, state-of- the-art product portfolio for rapid substance abuse testing available on the market today. ORALscreen is a highly sensitive, simple-to-use, reliable and disposable drug test that within minutes detects the presence of specific illegal substances, including marijuana, cocaine, opiates, methamphetamine and MDMA, also known as Ecstasy. The advantage of oral testing is that it may be performed in public and eliminates the embarrassment and chain-of-custody issues present with urine testing. ORALscreen cannot be adulterated in any way, and there are no substances that may be ingested that would result in a false negative result. Using a few strands of hair, the Company's HAIRscreen test can detect a history of drugs-of-abuse use over a 90-day period. Like ORALscreen, HAIRscreen cannot be adulterated to produce a false negative.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market, disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of- abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(TM), a laboratory-based hair test for detecting long-term drug abuse. Additionally, Avitar manufactures and markets HYDRASORB(TM), an absorbent topical dressing for moderate to heavy exudating wounds. In the estimated $25 billion in vitro diagnostics market, Avitar is developing diagnostic strategies for disease and clinical testing. Some examples include influenza, diabetes and pregnancy. For more information, see Avitar's website at avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Chief Financial Officer
Lippert/Heilshorn and Associates